144 related articles for article (PubMed ID: 29425684)
1. Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.
Ricciardelli C; Lokman NA; Sabit I; Gunasegaran K; Bonner WM; Pyragius CE; Macpherson AM; Oehler MK
Cancer Lett; 2018 May; 421():51-58. PubMed ID: 29425684
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.
Flick MB; O'Malley D; Rutherford T; Rodov S; Kamsteeg M; Hao XY; Schwartz P; Kacinski BM; Mor G
J Soc Gynecol Investig; 2004 May; 11(4):252-9. PubMed ID: 15120700
[TBL] [Abstract][Full Text] [Related]
3. 4-Methylumbelliferone Inhibits Cancer Stem Cell Activation and Overcomes Chemoresistance in Ovarian Cancer.
Lokman NA; Price ZK; Hawkins EK; Macpherson AM; Oehler MK; Ricciardelli C
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31443261
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.
Lokman NA; Ho R; Gunasegaran K; Bonner WM; Oehler MK; Ricciardelli C
J Exp Clin Cancer Res; 2019 Jan; 38(1):10. PubMed ID: 30621740
[TBL] [Abstract][Full Text] [Related]
5.
Karekla E; Liao WJ; Sharp B; Pugh J; Reid H; Quesne JL; Moore D; Pritchard C; MacFarlane M; Pringle JH
Cancer Res; 2017 Apr; 77(8):2029-2039. PubMed ID: 28202521
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response.
Nakada S; Aoki D; Ohie S; Horiuchi M; Suzuki N; Kanasugi M; Susumu N; Udagawa Y; Nozawa S
Int J Gynecol Cancer; 2005; 15(3):445-52. PubMed ID: 15882168
[TBL] [Abstract][Full Text] [Related]
7. Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
Frederick PJ; Kendrick JE; Straughn JM; Della Manna DL; Oliver PG; Lin HY; Grizzle WE; Stockard CR; Alvarez RD; Zhou T; LoBuglio AF; Buchsbaum DJ
Int J Gynecol Cancer; 2009 Jul; 19(5):814-9. PubMed ID: 19574765
[TBL] [Abstract][Full Text] [Related]
8. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models.
Brodeur MN; Simeone K; Leclerc-Deslauniers K; Fleury H; Carmona E; Provencher DM; Mes-Masson AM
Sci Rep; 2021 Sep; 11(1):18183. PubMed ID: 34521878
[TBL] [Abstract][Full Text] [Related]
10. [Comparison between apoptosis cells count and ATP-bioluminescence assay in ovarian cancer chemosensitivity testing in vitro].
Lou J; Wang H; Liu S; Peng Z
Hua Xi Yi Ke Da Xue Xue Bao; 2002 Apr; 33(2):267-9. PubMed ID: 12575205
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells.
Peters D; Freund J; Ochs RL
Mol Cancer Ther; 2005 Oct; 4(10):1605-16. PubMed ID: 16227411
[TBL] [Abstract][Full Text] [Related]
12. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
15. [Chemosensitivity testing in ovarian cancer--prospects for the future].
Pogońska P; Wydra D; Serkies K; Kobierski J; Łojkowska A
Ginekol Pol; 2014 Sep; 85(9):695-8. PubMed ID: 25322542
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
18. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
[No Abstract] [Full Text] [Related]
19. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis.
Li Y; Hu W; Shen DY; Kavanagh JJ; Fu S
Am J Obstet Gynecol; 2009 Feb; 200(2):177.e1-9. PubMed ID: 19110234
[TBL] [Abstract][Full Text] [Related]
20. [Ex-vivo-chemoresponse testing of head and neck cancer: an old hat?].
Wichmann G; Körner C; Dietz A
Laryngorhinootologie; 2011 Aug; 90(8):464-8. PubMed ID: 21809229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
